MATRICELLULAR PROTEINS REPRESENT a group of nonstructural extracellular matrix (ECM) proteins exerting regulative functions likely through direct binding to other matrix proteins, to specific cell surface receptors, as well as to growth factors and cytokines (1, 3, 7, 32) . This subset of ECM proteins is dynamically expressed, does not serve obvious structural roles in the matrix but functions primarily to modulate cellular responses to other environmental factors. Known matricellular proteins include thrombospondins (TSP), secreted protein acidic and rich in cysteine (SPARC), osteopontin (OPN), tenascin C (TNC) and X (TNX), members of the CCN family including Cyr61 (cysteine-rich 61; CCN1), CTGF (connective tissue growth factor; CCN2), and Nov (nephroblastoma overexpressed; CCN3), as well as lectins and galectins, hevin, small leucine-rich proteoglycans, fibulin-5, and others (1, 3, 7, 32) .
They show low levels of basal expression in normal adult tissue but prompt upregulation in response to injury, during wound healing and tissue remodeling (1, 7, 32) . Cellular processes directly involving matricellular proteins are cell adhesion and migration, ECM deposition, cell survival, and apoptosis. Aberrant expression of matricellular proteins has been associated with roles in inflammation, injury repair, fibrotic diseases, tumor development, and progression.
In kidneys, increasing evidence exists that many of these matricellular proteins are involved in the development of tubulointerstitial fibrogenesis and renal disease progression (16, 18, 26, 27, 36) . CTGF, SPARC, TNC, and TSP-1, for example, have been implicated in the development of tubulointerstitial lesions in human and experimental diabetic nephropathy. In particular, CTGF expression is upregulated in proliferative and fibrotic interstitial lesions of various human renal diseases including diabetic nephropathy (24, 37) . CTGF mRNA levels were increased in the renal cortex of rats with streptozotocin-induced diabetes (37) . Moreover, CTGF overexpression in podocytes of mice worsened diabetic nephropathy, while CTGF knockdown in the kidney reduced both diabetic nephropathy and renal fibrosis (13, 40, 41) . There is also evidence that TSP-1 is a major activator of transforming growth factor (TGF-␤) in renal disease (16) . TSP-1 may participate in the development of tubulointerstitial fibrosis in mercuric chloride-induced renal tubulointerstitial fibrosis (34) , and a recent study found functional activity of the TSP-1/ TGF-␤ axis especially in the tubulointerstitium of patients with type-2 diabetic nephropathy (15) . Tenascin seems to be expressed in the normal medullary interstitium of kidneys but is ubiquitously present in areas with interstitial fibrosis and in experimental mesangial proliferative glomerulonephritis (19, 36) . Interstitial expression of SPARC has been reported to be most prominent in passive Haymann nephritis, chronic cyclosporine A nephropathy, and the remnant kidney model, as well as, to a lesser extent, in angiotensin II-infused animals (27) . In these experimental models, SPARC mRNA and protein were substantially increased at sites of tubulointerstitial fibrosis/ matrix expansion (27) , and in diabetic SPARC-null mice tubulointerstitial fibrosis was ameliorated compared with diabetic wild-type animals (35) . Transcriptome analysis using microarray technology in an adriamycin nephropathy model of renal tubulointerstitial fibrosis identified both pathways already implicated in the pathogenesis of tubulointerstitial fibrosis (e.g., the TGF-␤1-CTGF-fibronectin-1 pathway) and novel fibrosis-associated genes such as SPARC and matrilin-2 (31), further suggesting that matricellular proteins are likely to have an important role in renal fibrogenesis.
Of those factors in the peritubular microenvironment that induce or promote epithelial-mesenchymal transition (EMT), TGF-␤1 and its downstream Smad signaling seem to play an essential role in renal fibrosis (14, 22) . TGF-␤1 is not only the most potent EMT inducer but, as a sole factor, can also initiate and complete the entire course of EMT processes (22, 39) . The key role of TGF-␤1 in EMT is also consistent with the observation that its expression is universally upregulated in every kind of chronic kidney disease both in experimental models and in clinical settings (2) . However, the list of EMT regulatory factors likely to be involved in renal fibrogenesis is constantly growing and includes various cytokines and growth factors (22) . In this context, it has recently been demonstrated that oncostatin M (OSM)-specific receptor ␤-subunit (OSMR␤) expression is upregulated by activated peripheral blood mononuclear cell-conditioned medium, which promoted alterations in tubular epithelial cell differentiation in vitro, indicative of EMT (25) . Furthermore, OSM was able to attenuate Ncadherin, E-cadherin, and claudin-2 expression and to increase vimentin, collagen type I, and FSP1 expression in human proximal tubular cells (PTC) when administered as the only ligand in the absence of any additional growth supplements (28) . These effects were associated with OSM-induced human PTC scattering in three-dimensional collagen matrices, further suggesting that this IL-6 family member is able to induce cellular events indicative of tubular EMT (28) . However, preliminary microarray analysis of OSM-stimulated human PTC revealed evidence that OSM might also have antifibrotic effects and may thus represent a cytokine which has the ability to act as both a profibrotic ligand and an antifibrotic mediator depending on the tubular epithelial cell microenvironment and/or specific injury (28) . Thus it was the aim of the present study to investigate potential antifibrotic effects mediated by the IL-6 family member OSM in human PTC. Specifically, we studied whether OSM has the ability to inhibit profibrotic mechanisms triggered by TGF-␤1 such as the expression of the matricellular proteins SPARC, TNC, TSP-1, with a special focus on CTGF.
METHODS

Reagents.
Cell culture reagents were obtained from GIBCO (Life Technologies, Lofer, Austria). OSM was purchased from Sigma (St. Louis, MO), TGF-␤1 from R&D Systems (Minneapolis, MN) and dorsomorphin dihydrochloride as well as SB431242 from Tocris Bioscience (Ellisville, MO). Mouse anti-human gp130 (MAB628) was purchased from R&D Systems. 5-Aza-2=-deoxycytidine (AZA) and all other reagents were obtained from Sigma.
Cell culture. Human kidney 2 (HK-2) cells obtained from American Type Culture Collection (Rockville, MD) were cultured in keratinocyte-serum free medium containing 10% FBS, 5 ng/ml recombinant epidermal growth factor (rEGF), 0.05 mg/ml bovine pituitary extract, 100 U/ml penicillin, and 100 g/ml streptomycin (28, 30) . Cells were grown at 37°C in a humidified 5% CO 2 atmosphere, and split at a 1:5 ratio, once a week. After growth to a subconfluent state, cells were washed once, made quiescent by incubation in serum-and supplement-free medium for 48 h, and then used for experiments. Stimulations with OSM or with TGF-␤1 were performed in the absence of serum and any other growth supplements. RPTEC/TERT1 cells (38) were propagated in DMEM-Ham's F-12, 5 mM glucose (1:1) medium supplemented with 5 g/ml insulin, 5 g/ml transferrin, 5 ng/ml sodium selenite, 10 ng/ml recombinant human EGF, 36 ng/ml hydrocortisone, 2 mM L-glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin. Cells were grown at 37°C in a humidified 5% CO 2 atmosphere and split at a 1:3 ratio once a week, or cultured to confluence and then used for experiments.
Western blot analysis. Cells were washed with ice-cold PBS and lysed in ice-cold RIPA lysis buffer [50 mM Tris·HCl, pH 7.5, 150 mM NaCl, 50 mM NaF, 5 mM EDTA, 0.5% deoxycholic acid, 40 mM ␤-glycerophosphate, 1 mM sodium orthovanadate, 10% protease inhibitor cocktail for mammalian tissues (Sigma), 0.1% SDS, 1% Triton X-100] for 20 min at 4°C. Insoluble material was removed by centrifugation at 12,000 g for 15 min at 4°C. The protein content of the samples was determined using a microbicinchoninic acid assay (Pierce, Fisher Scientific) or Coomassie protein assay (Pierce, Fisher Scientific) with BSA as a standard. Cell lysates were matched for protein, separated on 10% SDS-PAGE, and transferred to a polyvinylidene difluoride microporous membrane. Subsequently, membranes were stained with one of the following specific antibodies: goat anti-CTGF (L-20), rabbit anti-ERK2 (C-14), goat anti-Smad2/3 (N-19), mouse anti-Smad2/3 (C-8), goat anti-P-Smad2/3 (Ser423/425), rabbit anti-Smad1/5/8 (N-18)-R (Santa Cruz Biotechnology, Santa Cruz, CA), mouse anti-␤-actin (Sigma), P-Smad1/5/8, rabbit antiStat1, rabbit anti-P-Stat1 (Tyr701), rabbit anti-Stat3, or rabbit anti-PStat3 (Tyr705; Cell Signaling Technology, Danvers, MA). After extensive washing of the sheets in TBS, 0.1% Tween 20, the primary antibodies were detected using horseradish peroxidase-conjugated goat anti-rabbit IgG (Santa Cruz Biotechnology), goat anti-mouse IgG (Sigma), or rabbit anti-goat IgG (Santa Cruz Biotechnology), visualized by LumiGLO Western Blot Detection system (Cell Signaling Technology).
RNA isolation and real-time PCR analysis. Total RNA was isolated from HK-2 cells using the RNeasy Mini Kit (Qiagen, Valencia CA). For each sample, 1 g RNA was reverse transcribed into cDNA with a High Capacity cDNA reverse Transcription kit (Applied Biosystems, Foster City, CA) in a 20-l reaction according to the manufacturer's instructions. The cDNA was analyzed on the 7500 Fast Real-Time PCR System (Applied Biosystems) using the following inventoried TaqMan Gene Expression Assays: GAPDH (Hs99999905_ m1), forkhead box protein FOXC2 (Hs00270951_s1), TNC (Hs00233648_m1), SPARC (Hs00277762_m1), CTGF (Hs00170014_m1), and THBS1 (Hs00962914_m1). Each reaction contained 10 l of Gene Expression Master Mix, 1 l of TaqMan Gene Expression Assay, 5 l cDNA, and 4 l H 2O. Reactions were prepared in duplicate for each sample and incubated at 50°C for 2 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. A relative quantification method was used to analyze the real-time PCR data. The fractional cycle number at which the amount of amplified target reached a threshold is the CT number, the mean CT for each gene was determined, and the relative amounts of transcripts for each gene were normalized to the reference gene GAPDH as follows: ⌬CT ϭ CT (gene of interest) Ϫ CT (GAPDH). The ⌬CT was linearized according to the formula 2-dCT to determine the relative expression of each gene of interest. 
RESULTS
OSM inhibits TGF-␤1-induced expression of FoxC2 mRNA in human PTC line HK-2.
In the early inflammatory phase of renal fibrosis, cytokines produced by infiltrating cells play a decisive role in initiating EMT (22) . OSM from conditioned media of activated peripheral blood mononuclear cells, for example, promotes tubular EMT in vitro and induces cellular events indicative of tubular EMT (25, 28) . Results obtained in preliminary microarray analyses led us to speculate that OSM might represent a cytokine with the capability to act as both a pro-EMT molecule and a pro-MET mediator depending on the cellular microenvironment and/or a specific injury (28) . To gain further insight into the molecular mechanisms triggered by this IL-6 family member in human PTCs, we first studied mRNA expression of FoxC2, which has recently been recognized as an important transcriptional mediator of EMT, that can program cellular traits associated with dedifferentiation, migration, and metastasis (23) . Forty-eight-hour stimulation of quiescent HK-2 cells with 10 ng/ml of the EMT promoter TGF-␤1 led to a 3.1-fold upregulation of FoxC2 mRNA ( Fig. 1 ) compared with unstimulated controls (n ϭ 4; P Ͻ 0.01). Administration of 10 ng/ml OSM alone did not significantly affect basal FoxC2 mRNA expression (Fig. 1) . When administered together with TGF-␤1, however, OSM suppressed TGF-␤1-mediated upregulation of FoxC2 mRNA after 48 h of treatment. In the presence of OSM, TGF-␤1-stimulated FoxC2 mRNA expression was reduced to a level of 1.4-fold (n ϭ 4; P ϭ 0.014). These results suggest that OSM is able to inhibit TGF-␤1-mediated upregulation of this pleiotropic EMT inducer.
OSM inhibits basal and TGF-␤1-induced matricellular protein expression in human PTCs. Some of the main characteristics of matricellular proteins such as SPARC, TSP-1, TNC, and CTGF are 1) high levels of expression during development and in response to injury, 2) regulation of de-adhesion and migration, as well as 3) binding to cell surface receptors, ECM components, growth factors, cytokines, and proteases (1, 7, 26) . In addition, matricellular proteins have been implicated in tubulointerstitial fibrogenesis and renal disease progression. Thus we next examined the effects of OSM on the expression of the four matricellular proteins, i.e., SPARC, TSP-1, TNC, and CTGF, in unstimulated and TGF-␤1-treated human PTC. TGF-␤1 (10 ng/ml) led to a strong and time-dependent induction of mRNA expression of all four matricellular proteins (data not shown). TGF-␤1-stimulated mRNA expression of SPARC (2.1-fold; n ϭ 3), TSP-1 (7.5-fold; n ϭ 3), and TNC (10.1-fold; n ϭ 4) was highest after 24 h of treatment (P Ͻ 0.01). In contrast, mRNA expression of the immediate early gene CTGF was strongly induced as early as 1 h after administration of TGF-␤1, showed its highest mRNA level (4.2-fold) after 3 h of incubation (n ϭ 4; P Ͻ 0.01), and remained upregulated for at least 24 h (n ϭ 4; P Ͻ 0.05). Western blot analysis of CTGF protein expression confirmed the data obtained from real-time PCR analysis. Similarly to the timedependent expression of CTGF mRNA, 10 ng/ml TGF-␤1 led to a time-dependent induction of CTGF protein levels ( Fig. 2A) . Induction of CTGF protein started after 3 h of incubation with the cytokine, peaked after 6 h of stimulation and lasted for at least 24 h. In contrast to TGF-␤1, 10 ng/ml OSM repressed basal CTGF protein expression after 24 h of treatment ( Fig. 2A) . The CTGF double band obtained in soluble PTC lysates most likely corresponds to the glycosylated and nonglycosylated form of the protein (4). Furthermore, when administered alone, 10 ng/ml TGF-␤1 led to a strong 4.5-and 5.2-fold stimulation of CTGF mRNA expression after 12 and 24 h, respectively (n ϭ 4; P Ͻ 0.01 and P Ͻ 0.001) (Fig.  2B ). When both ligands were administered together, 10 ng/ml OSM significantly suppressed TGF-␤1-induced CTGF mRNA expression to a value of 1.3-fold after 24 h (n ϭ 4; P Ͻ 0.01) (Fig. 2B) .
Subsequent experiments revealed evidence that OSM also has the ability to inhibit basal and TGF-␤1-induced mRNA expression of the other three matricellular proteins investigated. When administered alone, 10 ng/ml TGF-␤1 again led to a strong stimulation of SPARC, TSP-1, and TNC mRNA expression after 12 and 24 h (n ϭ 4; P Ͻ 0.01 and P Ͻ 0.001) (Fig. 3 , A-C), while OSM alone inhibited basal mRNA expression of SPARC, TSP-1, and TNC after 12 and 24 h of treatment (n ϭ 4; P Ͻ 0.01 and P Ͻ 0.001) (Fig. 3 , A-C). TGF-␤1-induced mRNA expression of matricellular proteins in the absence of OSM after 24 h was 2.5-fold (SPARC), 8.1-fold (TSP-1), and 6.7-fold in the case of TNC. When both ligands were administered together, 10 ng/ml OSM significantly suppressed TGF-␤1-induced mRNA expression of all three matricellular proteins after 12 and 24 h (Fig. 3 , A-C). While TGF-␤1-mediated induction of SPARC mRNA expression was completely abolished by OSM after 24 h (n ϭ 4; P Ͻ 0.001 compared with TGF-␤1-stimulated cells) (Fig. 3A) , TGF-␤1-induced mRNA expression of TSP-1 and TNC was reduced to values of 3.1-and 2.6-fold, respectively (n ϭ 4; P Ͻ 0.01) (Fig. 3 , B and C). Together, these results suggest that OSM has the ability to attenuate basal and TGF-␤1-induced expression of SPARC, TSP-1, TNC, and CTGF in human PTCs.
OSM-mediated inhibition of TGF-␤1-induced matricellular protein expression occurs independently of the sequence of ligand administration. Next, it was important to us to study whether it is necessary to administer OSM together or even before TGF-␤1 stimulation to inhibit TGF-␤1-induced matricellular protein expression. To this end, matricellular protein expression was investigated in HK-2 cells, which were either stimulated by simultaneous administration of TGF-␤1 and were serum-and supplement-starved for 24 h and subsequently stimulated for 48 h with 10 ng/ml TGF-␤1 alone, 10 ng/ml OSM alone, or both ligands together (TGF-␤1ϩOSM) compared with unstimulated controls. Real-time PCR analysis was performed as detailed in METHODS. Data are presented as fold-induction above FoxC2 mRNA control levels after normalization to GAPDH mRNA expression. Each data point indicates the average of 4 independent experiments, with error bars corresponding to SE (*P Ͻ 0.05, **P Ͻ 0.01).
OSM for 24 h or after preincubation with one of the two ligands for 5 min or 1 h and subsequent addition of the second ligand. As depicted in Figs. 4 and 5, 10 ng/ml TGF-␤1 alone again stimulated mRNA expression of all four matricellular proteins, while 10 ng/ml OSM alone inhibited their basal mRNA expression. Simultaneous administration of TGF-␤1 and OSM led to a strong inhibition of TGF-␤1-stimulated mRNA expression of SPARC (Fig. 4A) , TSP-1 (Fig. 4B) , and TNC (Fig. 4C ) after 24 h of treatment (n ϭ 3-6; P Ͻ 0.001). However, OSM exerted this inhibitory effect not only when the cells were preincubated with OSM (for 5 min or 1 h) before TGF-␤1 administration but also after preincubation of the cells with TGF-␤1 (5 min or 1 h) preceding OSM administration (n ϭ 3-6; P Ͻ 0.001) (Fig. 4, A-C) . Identical results were obtained for CTGF mRNA expression (Fig. 5A ), which were verified by Western blot analysis (Fig. 5B) . Furthermore, OSM blocked TGF-␤1-induced CTFG mRNA expression even when cells were preincubated with TGF-␤1 for 3, 6, or 12 h (Fig.  5C ). These results suggest that OSM-mediated inhibition of TGF-␤1-stimulated mRNA expression of SPARC, TSP-1, TNC, or CTGF and of CTGF protein occurs irrespective of both the sequence of ligand administration and the duration of preincubation of either one of the two ligands.
Inhibitory effect of OSM on TGF-␤1-induced CTGF mRNA expression is effective after 2 h and not affected by inhibition of DNA methylation. To investigate the time point and underlying mechanism of OSM's inhibitory effect on TGF-␤1-stimulated matricellular protein expression, we subsequently focused our experimental effort on CTGF and performed time course experiments of CTGF mRNA expression with TGF-␤1 alone and TGF-␤1 in the presence of OSM compared with unstimulated control cells. Induction of CTGF mRNA expression by TGF-␤1 (10 ng/ml) started as early as 15 min after ligand administration and was highest after 2 h (Fig. 6 ). In the presence of OSM, TGF-␤1-mediated CTGF mRNA expression showed a similar time-dependent increase up to 1 h but was significantly inhibited at the 2-h time point and later (n ϭ 4; P Ͻ 0.05 and P Ͻ 0.01) (Fig. 6 ). Thus the mechanisms involved in OSM's inhibitory effects on TGF-␤1-induced CTGF mRNA expression are likely to become effective between 1 and 2 h after ligand administration.
Alterations of DNA methylation in the promoter region of the CTGF gene play an important role in the regulation of its expression (5, 20) . Thus we next utilized the DNA methyltransferase inhibitor AZA to address whether alterations of the chromatin structure play a role in the OSM-mediated inhibition of CTGF expression in proximal tubular HK-2 cells. Quiescent cells were incubated with 2.5 M AZA or DMSO for 24 h and were then stimulated with TGF-␤1 alone, OSM alone, or both ligands together for an additional 24 h (Fig. 7) . In the absence of AZA, OSM led to a strong and significant inhibition of TGF-␤1-mediated CTGF mRNA expression after 24 h (n ϭ 5; P Ͻ 0.05) (Fig. 7A) . Preincubation of cells with the DNA methyltransferase inhibitor for 24 h upregulated basal CTGF mRNA expression 2.1-fold and TGF-␤1-stimulated CTGF mRNA expression from 2.4-fold (in the absence of AZA) to 6.0-fold (Fig. 7A) . TGF-␤1-stimulated mRNA expression of CTGF was repressed by OSM from 2.4-fold to a value of 0.51-fold in the absence of the DNA methyltransferase inhibitor and showed a decrease from 6.0-fold to a value of 1.6-fold in the presence of AZA (n ϭ 5; P Ͻ 0.01) (Fig. 7A) . Similar effects of AZA on CTGF protein expression were obtained by Western blot analysis (Fig. 7B) , which corroborates the finding that this DNA methyltransferase inhibitor does not attenuate OSM's inhibitory effect on TGF-␤1-stimulated CTGF expression.
OSM rapidly induces long-lasting phosphorylation of Stat1 and Stat3 and transient phosphorylation of Smad2/3 but not Smad1/5/8 in human PTC. To elucidate the intracellular signaling mechanisms, which might be involved in OSM-mediated inhibition of TGF-␤1-induced expression of CTGF in human PTC, we next investigated phosphorylation of Stat and Smad signaling pathways. We have previously published that OSM is a strong stimulator of both Stat1 phosphorylation and Stat3 phosphorylation in HK-2 cells (28) and now show that OSM but not TGF-␤1 rapidly stimulated phosphorylation of both Stat1 and Stat3 in these cells, which lasted for at least 6 HK-2 cells were serum-and supplement-starved for 48 h and subsequently stimulated for 12 and 24 h with 10 ng/ml TGF-␤1 alone, 10 ng/ml OSM alone, or with these 2 cytokines together (TGF-␤1ϩOSM). Real-time PCR analysis was performed as detailed in METHODS. Data are presented as fold-induction above CTGF mRNA control levels after normalization to GAPDH mRNA expression. Each data point indicates the average of 4 independent experiments, with error bars corresponding to SE (**P Ͻ 0.01, ***P Ͻ 0.001).
h (Fig. 8A) , and in the case of Stat3 even as long as 48 h (28) . Interestingly, OSM also led to a rapid and transient phosphorylation of Smad2/3 but not Smad1/5/8, while administration of TGF-␤1 was associated with a slow, long-lasting induction of Smad2/3 phosphorylation and a rapid but transient phosphorylation of Smad1/5/8 (Fig. 8B) . Similar differential effects of OSM and TGF-␤1 on Smad signaling were obtained in RPTEC/TERT1 cells, which represent another well-differentiated human proximal tubular cell line immortalized by ectopic expression of the catalytic subunit of telomerase (TERT) (38) (Fig. 8C) .
Differential effects of type I activin receptor-like kinase inhibitors on TGF-␤1-and OSM-induced Smad phosphorylation and CTGF mRNA expression.
To elucidate the signaling mechanisms involved in TGF-␤1-and OSM-mediated effects on CTGF mRNA expression in human PTC, we next studied phosphorylation of Smad2/3 and Smad1/5/8 as well as CTGF mRNA expression in the presence of distinct small molecule Fig. 3 . OSM inhibits basal and TGF-␤1-stimulated mRNA expression of secreted protein acidic and rich in cysteine (SPARC), thrombospondin (TSP)-1, and tenascin C (TNC) in human PTCs. HK-2 cells were serum-and supplement-starved for 48 h and subsequently stimulated for 12 and 24 h with 10 ng/ml TGF-␤1 alone, 10 ng/ml OSM alone, or these 2 cytokines together (TGF-␤1ϩOSM). Inhibition of basal and TGF-␤1-mediated mRNA expression of SPARC (A), TSP-1 (B), and TNC (C) by OSM is shown. Real-time PCR analysis was performed as detailed in METHODS. Data are presented as fold-induction above mRNA control levels of the respective matricellular protein (SPARC, TSP-1, or TNC) after normalization to GAPDH mRNA expression. Each data point indicates the average of 4 independent experiments, with error bars corresponding to SE (*P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001). Fig. 4 . Inhibitory effect of OSM on TGF-␤1-induced expression of SPARC, TSP-1, and TNC does not depend on the sequence of ligand administration. HK-2 cells were serum-and supplement-starved for 48 h and were then either left untreated (Co) or stimulated for 24 h with 10 ng/ml TGF-␤1 alone, 10 ng/ml OSM alone, or with combinations of these 2 cytokines as follows: simultaneous administration of TGF-␤1 and OSM (TGF-␤1ϩOSM), preincubation of TGF-␤1 for 5 min or 1 h and subsequent addition of OSM (TGF-␤1 5 min/1 h preϩOSM), or preincubation of OSM for 5 min or 1 h and subsequent addition of TGF-␤1 (OSM 5 min/1 h preϩTGF-␤1). mRNA expression of SPARC (A), TSP-1 (B) and TNC (C) are depicted. A-C: real-time PCR analysis was performed as detailed in METHODS. Data are presented as fold-induction above mRNA control levels of the respective matricellular protein (SPARC, TSP-1, or TNC) after normalization to GAPDH mRNA expression. Six independent experiments were performed for the 5-min preincubation studies, while 3 independent experiments were analyzed for the 1-h preincubation studies. All other data points indicate the average of 6 independent experiments, with error bars corresponding to SE (***P Ͻ 0.001).
inhibitors of type I activin receptor-like kinase (ALK) receptors. The small-molecule compound SB431542 represents an inhibitor of TGF-␤1 superfamily type I receptors ALK4, ALK5, and ALK7 (17) (see Fig. 11 ). SB431542 (10 M)
abolished not only basal Smad2/3 phosphorylation but also TGF-␤1-induced Smad2/3 phosphorylation after 1 and 3 h (Fig. 9A) . Interestingly, this ALK4/5/7 inhibitor also blocked TGF-␤1-stimulated transient Smad1/5/8 phosphorylation (Fig.  9A) . Similar effects were obtained in RPTEC/TERT1 cells (Fig. 9B ). More importantly, administration of SB431542 led to a strong inhibition of CTGF mRNA expression in the absence and in the presence of TGF-␤1 and/or OSM after 3 h of incubation (Fig. 9C) , suggesting that long-term inhibition of Smad2/3 phosphorylation by SB431542 is able to almost completely abolish basal and TGF-␤1-stimulated CTGF mRNA expression. Dorsomorphin, another small-molecule inhibitor, has been reported to selectively inhibit bone morphogenic protein (BMP) type I receptors ALK2, ALK3, and ALK6, and thus BMP-mediated Smad1/5/8 phosphorylation and target gene transcription (42) (see Fig. 11 ). In proximal tubular HK-2 cells, 10 M dorsomorphin blocked not only early and transient TGF-␤1-induced Smad1/5/8 phosphorylation but also basal Smad2/3 phosphorylation after 1 and 3 h as well as TGF-␤1-induced Smad2/3 phosphorylation after 1 h (Fig. 9A) . However, in both proximal tubular cell lines, HK-2 ( Fig. 9A) and RPTEC/TERT1 (Fig. 9B) , dorsomorphin superinduced Smad2/3 phosphorylation in the presence of TGF-␤1 and/or OSM after 3 h of incubation compared with cells stimulated with these two cytokines in the absence of dorsomorphin. These results on TGF-␤1-and OSM-mediated Smad phosphorylation were associated with specific effects of dorsomorphin on CTGF mRNA expression (Fig. 9C) . In the absence of this compound, TGF-␤1-stimulated phosphorylation of Smad1/5/8 (after 1 h) and Smad2/3 (after 3 h) was associated with induction of HK-2 cells were serum-and supplement-starved for 48 h and were then left untreated (Co), stimulated for either 24 h (A and B) or for the depicted periods of time (C) with 10 ng/ml TGF-␤1 alone, 10 ng/ml OSM alone, or with combinations of these 2 cytokines as follows: simultaneous administration of TGF-␤1 and OSM (TGF-␤1ϩOSM), preincubation of TGF-␤1 for the respective period of time and subsequent addition of OSM (TGF-␤1 min/h preϩOSM), or preincubation of OSM for the respective period of time and subsequent addition of TGF-␤1 (OSM min/h preϩTGF-␤1). Expression of CTGF mRNA (A and C) and CTGF protein (B) is depicted. A and C: real-time PCR analysis was performed as detailed in METHODS. Data are presented as fold-induction above CTGF mRNA control levels after normalization to GAPDH mRNA expression. Six independent experiments were performed for the 5-min preincubation studies, while 3 independent experiments were analyzed for the 1-, 3-, 6-, and 12-h preincubation studies. All other data points indicate the average of 6 (A) or 3 (C) independent experiments, with error bars corresponding to SE (***P Ͻ 0.001). B: protein-matched samples of stimulated cells and unstimulated controls were separated on 10% SDS-PAGE and analyzed by Western immunoblotting for protein expression of CTGF and ERK2. The results from 1 representative Western blot of n ϭ 3 separate experiments are depicted. Fig. 6 . Time-dependent effect of OSM on TGF-␤1-induced CTGF mRNA expression. HK-2 cells were serum-and supplement-starved for 48 h and were then stimulated with 10 ng/ml TGF-␤1 alone or with the combination of TGF-␤1 and OSM (10 ng/ml) for the indicated periods of time compared with untreated controls. Real-time PCR analysis was performed as detailed in METHODS. Data are presented as fold-induction above CTGF mRNA control levels after normalization to GAPDH mRNA expression. Each data point indicates the average of 4 independent experiments, with error bars corresponding to SE (*P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001).
CTGF mRNA expression, while OSM inhibited basal and TGF-␤1-mediated CTGF mRNA expression (Fig. 9C ). In contrast, in the presence of dorsomorphin, basal Smad2/3 phosphorylation and CTGF mRNA expression were abolished after 3 h, while TGF-␤1-mediated superinduction of Smad2/3 phosphorylation was associated with TGF-␤1-stimulated CTGF mRNA expression (Fig. 9) . Interestingly, although dorsomorphin led to a prolongation of OSM-mediated Smad2/3 phosphorylation (Fig. 9A) , this did not affect OSM's inhibitory action on TGF-␤1-induced CTGF mRNA expression (Fig. 9C) . 7 . Effects of DNA methyltransferase inhibitor 5-aza-2=-deoxycytidine (AZA) on CTGF mRNA and protein expression in human PTCs. HK-2 cells were serum-and supplement-starved for 24 h and then pretreated either with vehicle alone (DMSO) or with AZA (2.5 M) for another 24 h. Subsequently, cells were stimulated for 24 h with 10 ng/ml TGF-␤1 alone, 10 ng/ml OSM alone, or with a combination of the 2 cytokines. A: TGF-␤1-stimulated mRNA expression of CTGF was repressed by OSM from 2.4-fold to a value of 0.51-fold in the absence of the DNA methyltransferase inhibitor (n ϭ 5; *P Ͻ 0.05) and showed a decrease from 6.0-fold to a value of 1.6-fold in the presence of AZA (n ϭ 5; **P Ͻ 0.01). B: AZA augments basal and ligand-stimulated CTGF protein expression without affecting ERK2 protein expression. OSM still attenuates basal and TGF-␤1-stimulated CTGF protein expression in the presence of AZA. Protein-matched samples of stimulated cells and unstimulated controls were separated on 10% SDS-PAGE and analyzed by Western immunoblotting for protein expression of CTGF and ERK2. The results from 1 representative Western blot of n ϭ 3 separate experiments are depicted.
OSM receptor blockade inhibits OSM-stimulated phosphorylation of Stat1/3 and OSM-mediated inhibition of TGF-␤1-
blocking antibody against the OSM receptor subunit gp130 (2 g/ml) for 2 h before treatment with OSM abolished OSMstimulated phosphorylation of Stat1 and Stat3 without affecting TGF-␤1-mediated phosphorylation of Smad2/3 or Smad1/5/8. In addition, administration of the gp130 antibody blocked OSM's transient stimulatory effect on Smad2/3 phosphorylation, suggesting that this OSM effect depends on OSM receptor subunit gp130. Interestingly, inhibition of OSM-driven Stat1/3 phosphorylation after 1 h was associated with loss of OSM's inhibitory effect on basal and TGF-␤1-stimulated CTGF mRNA expression after 3 h (Fig. 10B) . Together, these results suggest that, while TGF-␤1 stimulates CTGF mRNA expression predominantly via the Smad2/3 signaling pathway, OSM's inhibitory effect on basal and TGF-␤1-induced CTGF mRNA expression may at least partially be mediated by Stat1 and/or Stat3 (Fig. 11) . Fig. 9 . Effects of TGF-␤ type I receptor kinase inhibitors SB431542 and dorsomorphin on TGF-␤1-and OSM-mediated phosphorylation of Smad signaling molecules and CTGF mRNA expression in human PTC. Cells were serum-and supplement-starved for 48 h and then stimulated with 10 ng/ml TGF-␤1 alone, 10 ng/ml OSM alone, or a combination of the 2 cytokines for 1 and 3 h after preincubation for 1 h with vehicle (DMSO), SB431542 (10 M), or dorsomorphin (10 M). Samples of stimulated cells and unstimulated controls were analyzed by Western immunoblotting and real-time PCR as described in METHODS. A: effects of SB431542 and dorsomorphin on Smad2/3 phosphorylation (P-Smad2/3), Smad2/3 protein expression (Smad2/3), Smad1/5/8 phosphorylation (P-Smad1/5/8), and Smad1/5/8 protein expression (Smad1/5/8) in HK-2 cells. The results from 1 representative Western blot of 3 separate experiments are depicted. B: effects of SB431542 and dorsomorphin on Smad2/3 phosphorylation (P-Smad2/3), Smad2/3 protein expression (Smad2/3), Smad1/5/8 phosphorylation (P-Smad1/5/8), and Smad1/5/8 protein expression (Smad1/5/8) in RPTEC/TERT1 cells. The results from 1 representative Western blot of 3 separate experiments are depicted. C: HK-2 cells were serum-and supplement-starved for 48 h and then stimulated with 10 ng/ml TGF-␤1 alone, 10 ng/ml OSM alone, or with a combination of the 2 cytokines for 3 h. Data are presented as fold-induction above CTGF mRNA control levels after normalization to GAPDH mRNA expression. Each data point indicates the average of 5 independent experiments, with error bars corresponding to SE (*P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 vs. DMSO controls or as depicted).
DISCUSSION
OSM represents a cytokine that has been discussed not only in the context of pathophysiological mechanisms associated with inflammatory kidney disease and tubulointerstitial fibrogenesis but also as a mediator for renal tissue remodeling and regeneration (22, 25, 28) . We and others have previously reported OSM-induced effects in human PTC indicative of EMT (25, 28) . With respect to its potential role in renal tissue remodeling and regeneration, we now evaluated the effects of OSM on the expression of four matricellular proteins in human PTC, with a specific focus on CTGF. Here, we provide the first evidence that OSM is also able to act as an inhibitor of the profibrotic effector cytokine TGF-␤1. In human PTC, OSM inhibits not only TGF-␤1-induced expression of the transcriptional EMT inducer FoxC2 but also basal and TGF-␤1-induced expression of all four matricellular proteins investigated, namely, SPARC, TSP-1, TNC, and CTGF. This inhibitory effect on matricellular protein expression is independent of the sequence of ligand administration and, with respect to CTGF mRNA expression, is not affected by inhibition of DNA methylation. Detailed analysis of the time dependency of OSM's inhibitory effect on TGF-␤1-induced CTGF mRNA expression revealed that it starts as early as 2 h after ligand administration and lasts for at least 24 h.
Some of the distinguishing characteristics of matricellular proteins such as SPARC, TSP-1, TNC, and CTGF include 1) high levels of expression during development and in response to injury; 2) binding to many cell-surface receptors, components of the ECM, growth factors, cytokines, and proteases; and 3) induction of de-adhesion or counteradhesion (1) . Matricellular proteins seem to have a regulatory function in all aspects of physiological and pathological stroma rearrangement, and their activity is often related to inflammation, fibrogenesis, and disease progression (6, 32) . In kidneys, especially CTGF together with TGF-␤ form a major axis in chronic renal diseases including renal fibrosis (18, 26, 29) . At a cellular level, CTGF has been reported to induce epithelial-to-mesenchymal transition (EMT) by stimulating the migratory phenotype of PTC via induction of phenotypic changes, alterations in ECM composition, and induction of TNC (10) . In addition, it has been shown that CTGF can promote EMT in human renal tubular epithelial cells in vitro, both directly and as a downstream mediator of TGF-␤ (43) . In support of the potential role of CTGF in EMT in vivo, Frazier et al. (9) observed CTGF, TGF-␤, and PDGF expression in close proximity to epithelial cells in transition to the myofibroblast phenotype in the remnant model of renal fibrosis. The fact that OSM is a strong inhibitor of basal and TGF-␤1-induced expression of CTGF, SPARC, TSP-1, and TNC in human PTC not only represents the first evidence for a novel function of this IL-6 family member but also raises several questions regarding the underlying intracellular mechanisms of its action. To study these, we focused on the CTGF gene and further investigated OSM-and TGF-␤1-mediated intracellular signaling pathways and their role in CTGF mRNA expression.
For a long time, TGF-␤1 was known to signal predominantly through a receptor complex comprising TGF-␤ type I receptor ALK5 and TGF-␤ type II to activate receptor-regulated Smads (R-Smads) Smad2 and Smad3, which then transduce the signal to the nucleus. In general, binding of TGF-␤1 induces formation of a type II-type I receptor complex in which the constitutively active type II receptor phosphorylates and activates the type I receptor. Originally, this TGF-␤ superfamily signaling was reported to exist in essentially two branches: a TGF-␤/nodal/activin branch that signals through activation of Smad2/3, and a BMP/growth and differentiation factor branch that signals through Smad1/5/8 (33). However, this concept that one ligand activates one class of R-Smads was revised when it became clear that in endothelial cells, TGF-␤ activates both Smad2/3 and Smad1/5 through a heteromeric receptor complex comprising TGF-␤ receptor type II, ALK1, and ALK5 (11, 12) . In addition, ALK1 was shown to directly antagonize ALK5 signaling and induce biological responses opposite those of ALK5. Subsequently, this dual signaling by TGF-␤1 has been reported in a panel of normal epithelial cells, fibroblasts, and epithelium-derived tumor cell lines, both transformed and untransformed (8, 21) . We now confirm TGF-␤1-induced dual phosphorylation of both Smad2/3 and Smad1/5/8 in two distinct human PTC models (HK-2 and RPTEC/TERT1) and, in addition, studied the time dependence of these signaling events. In both PTC lines investigated, TGF-␤1 stimulated long-lasting phosphorylation of Smad2/3 and rapid but transient phosphorylation of Smad1/5/8 (Figs. 8, B and C, and 11 ). To our surprise, the IL-6 family member OSM did not only mediate rapid and long-lasting phosphorylation of Stat1 and Stat3 (28) (Fig. 8A) but also rapid and transient phosphorylation of Smad2/3 (Figs. 8, B and C, and 11 ). Administration of a small-molecule compound, SB431542, which represents an inhibitor of (TGF-␤ type I) ALK4, ALK5, and ALK7 (17), almost completely blocked basal and TGF-␤1-induced Smad2/3 phosphorylation as well as TGF-␤1-induced Smad1/5/8 phosphorylation after 1 h of incubation (Fig. 9, A and B) . Identical results were obtained in 1-h stimulation experiments utilizing another small-molecule compound, namely, dorsomorphin, which has been established as an inhibitor of (BMP type I) ALK2, ALK3, and ALK6 (42) . Together these results suggest that TGF-␤ type I receptors (ALK4/5/7) as well as BMP type I receptors (ALK2/3/6) may act in a synergistic fashion to induce ligand-mediated short-term phosphorylation of Smad2/3 and Smad1/5/8 (Fig. 11) . After 3 h of incubation, however, SB431542 abrogated Smad2/3 signaling in unstimulated and cytokine-stimulated cells (Fig. 9, A and B) , which was associated with almost complete inhibition of CTGF mRNA expression under identical experimental conditions (Fig. 9C) , suggesting that intact Smad2/3 signaling is necessary and sufficient for long-term TGF-␤1-induced CTGF mRNA expression (Fig. 11) . In addition, blockade of basal Smad2/3 phosphorylation associated with abolished basal CTGF mRNA expression was also obtained after 3 h in the presence of dorsomorphin (Fig. 9) , supporting the idea of a cooperative action of both TGF-␤ type I receptors and BMP type I receptors in the regulation of basal CTGF mRNA expression (Fig. 11) . In the presence of TGF-␤1 and/or OSM, however, Smad2/3 phosphorylation was superinduced by 3-h administration of the ALK2/3/6 inhibitor dorsomorphin (Fig. 9, A and  B) , which represents evidence for a BMP type I receptormediated inhibition of the Smad2/3 signaling pathway at later time points (Fig. 11) . The dorsomorphin-mediated superinduction of Smad2/3 phosphorylation in TGF-␤1-stimulated human PTC after 3 h was again associated with an increase in CTGF mRNA expression (Fig. 9C) . In contrast, OSM inhibited CTGF mRNA expression in the presence of TGF-␤1, albeit highly induced and persistent Smad2/3 phosphorylation (Fig. 9) , which is consistent with the idea that the inhibitory effect of OSM on TGF-␤1-induced CTGF mRNA expression is independent of Smad2/3 signaling. The time course of OSMinduced Stat1/3 phosphorylation (Fig. 8A) and CTGF mRNA expression in the presence of both TGF-␤1 and OSM (Fig. 6 ) led us to speculate that Stat1 and/or Stat3 might be involved in OSM's long-term inhibitory effect on TGF-␤1-induced CTGF mRNA expression. This idea was corroborated by experiments utilizing a function-blocking monoclonal antibody directed against the OSM receptor subunit gp130. While preincubation with anti-gp130 did not affect TGF-␤1-mediated phosphorylation of Smad2/3 or Smad1/5/8, it completely blocked OSMstimulated phosphorylation of Stat1 and Stat3 (Fig. 10A) . This was associated with a complete restoration of CTGF mRNA expression in unstimulated and TGF-␤1-stimulated human PTC in the presence of OSM (Fig. 10B) , suggesting that OSM-mediated inhibition of TGF-␤1-induced CTGF mRNA expression may at least partially be mediated by OSM receptor-driven Stat1 and/or Stat3 signaling pathways.
In summary we conclude that OSM is able to block basal and TGF-␤1-induced matricellular protein expression in human PTC and may thereby participate in tubulointerstitial protection and/or regeneration. As a consequence, OSM seems to have a dual role in the regulation of cellular mechanisms associated with renal tubulointerstitial fibrogenesis. Besides OSM-mediated induction of morphological alterations indicative of renal tubular EMT (25, 28) , it can act as an inhibitor of the profibrotic effector cytokine TGF-␤1. Depending on the cellular microenvironment and/or a specific injury (its duration, size, the cellular context, and the ligands produced), OSM may indeed have the ability to act as an anti-or profibrotic molecule (28) . With respect to the regulation of basal and early TGF-␤1-mediated CTGF mRNA expression, both TGF-␤ type I receptors and BMP type I receptors are likely to function in a cooperative fashion (Fig. 11) . At later time points, however, ALK4/5/7-mediated Smad2/3 phosphorylation seems to be the dominant signaling pathway driving TGF-␤1-stimulated CTGF mRNA induction in human PTC. It is tempting to speculate that the OSM-mediated inhibitory effect on basal and TGF-␤1-induced CTGF mRNA expression, which starts as early as 2 h after ligand administration, may at least partially be driven by Stat1-and/or Stat3-mediated signaling mechanisms.
